Literature DB >> 23873336

Incidence and aetiology of renal phosphate loss in patients with hypophosphatemia in the intensive care unit.

Anneke Bech1, Michiel Blans, Darryl Telting, Hans de Boer.   

Abstract

BACKGROUND: Hypophosphatemia is a common finding in patients in the intensive care unit (ICU). Its cause is often poorly understood.
PURPOSE: The aim of this study was to understand the incidence of renal phosphate loss in ICU-related hypophosphatemia, and to examine the role of phosphaturic hormones in its etiology.
METHODS: Plasma phosphate levels were measured on day 1, 3, 5 and 7 in 290 consecutive patients admitted to the ICU. Renal phosphate handling and phosphaturic hormones were studied in a subset of patients with phosphate levels <0.6 mmol/L. Renal phosphate loss was defined as a TmP/gfr < 0.6 mmol/L. MAIN
RESULTS: Hypophosphatemia developed in 24% of all patients. This mainly occurred within the first 3 days of stay and in patients with serum creatinine levels <150 μmol/L. Renal phosphate loss was present in 80% of patients who developed hypophosphatemia, and was not related to serum levels of parathyroid hormone (PTH), PTH-related protein (PTH-rp), fibroblast growth factor 23 (FGF-23), or calcitonin.
CONCLUSION: Hypophosphatemia in the ICU is commonly associated with renal phosphate loss. It mainly occurs within the first 3 days of admission, in particular in patients with preserved renal function. Renal phosphate loss is not explained by elevated PTH, PTH-rp, FGF-23 or calcitonin levels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23873336     DOI: 10.1007/s00134-013-2970-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  20 in total

1.  Renal function in cancer patients treated with hyperthermic isolated limb perfusion with recombinant tumor necrosis factor-alpha and melphalan.

Authors:  J H Zwaveling; H J Hoekstra; J K Maring; R J v Ginkel; H Schraffordt Koops; A J Smit; A R Girbes
Journal:  Nephron       Date:  1997       Impact factor: 2.847

Review 2.  Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit.

Authors:  N C Bugg; J A Jones
Journal:  Anaesthesia       Date:  1998-09       Impact factor: 6.955

3.  Hyponatremia, hypophosphatemia, and hypouricemia in a girl with macrophage activation syndrome.

Authors:  Kazuki Yamazawa; Kazuki Kodo; Jun Maeda; Sayu Omori; Mariko Hida; Tetsuya Mori; Midori Awazu
Journal:  Pediatrics       Date:  2006-12       Impact factor: 7.124

4.  Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines.

Authors:  V Barak; A Schwartz; I Kalickman; B Nisman; G Gurman; Y Shoenfeld
Journal:  Am J Med       Date:  1998-01       Impact factor: 4.965

5.  Intravenous phosphate in the intensive care unit: more aggressive repletion regimens for moderate and severe hypophosphatemia.

Authors:  Thierry Charron; Francis Bernard; Yoanna Skrobik; Nathalie Simoneau; Nadine Gagnon; Martine Leblanc
Journal:  Intensive Care Med       Date:  2003-07-05       Impact factor: 17.440

Review 6.  Treatment of hypophosphatemia in the intensive care unit: a review.

Authors:  Daniël A Geerse; Alexander J Bindels; Michael A Kuiper; Arnout N Roos; Peter E Spronk; Marcus J Schultz
Journal:  Crit Care       Date:  2010-08-03       Impact factor: 9.097

Review 7.  Homer Smith Award. Cellular mechanisms in proximal tubular Pi reabsorption: some answers and more questions.

Authors:  H Murer
Journal:  J Am Soc Nephrol       Date:  1992-06       Impact factor: 10.121

8.  Hypophosphatemia in critically ill patients.

Authors:  Satoshi Suzuki; Moritoki Egi; Antoine G Schneider; Rinaldo Bellomo; Graeme K Hart; Colin Hegarty
Journal:  J Crit Care       Date:  2012-12-21       Impact factor: 3.425

Review 9.  Physiological regulation and disorders of phosphate metabolism--pivotal role of fibroblast growth factor 23.

Authors:  Seiji Fukumoto
Journal:  Intern Med       Date:  2008-03-03       Impact factor: 1.271

10.  Human sepsis increases lymphocyte intracellular calcium.

Authors:  G P Zaloga; D Washburn; K W Black; R Prielipp
Journal:  Crit Care Med       Date:  1993-02       Impact factor: 7.598

View more
  5 in total

1.  Hypophosphatemia in Critically Ill Children: Risk Factors, Outcome and Mechanism.

Authors:  Satish Kumar Shah; Mohammad Irshad; Nandita Gupta; Sushil Kumar Kabra; Rakesh Lodha
Journal:  Indian J Pediatr       Date:  2016-07-09       Impact factor: 1.967

2.  Incidence of hypophosphatemia in advanced cancer patients: a recent report from a single institution.

Authors:  Taichi Yoshida; Daiki Taguchi; Koji Fukuda; Kazuhiro Shimazu; Masahiro Inoue; Katsunori Murata; Hiroyuki Shibata
Journal:  Int J Clin Oncol       Date:  2016-11-10       Impact factor: 3.402

3.  Year in review in Intensive Care Medicine 2013: I. Acute kidney injury, ultrasound, hemodynamics, cardiac arrest, transfusion, neurocritical care, and nutrition.

Authors:  Giuseppe Citerio; Jan Bakker; Matteo Bassetti; Dominique Benoit; Maurizio Cecconi; J Randall Curtis; Glenn Hernandez; Margaret Herridge; Samir Jaber; Michael Joannidis; Laurent Papazian; Mark Peters; Pierre Singer; Martin Smith; Marcio Soares; Antoni Torres; Antoine Vieillard-Baron; Jean-François Timsit; Elie Azoulay
Journal:  Intensive Care Med       Date:  2013-12-13       Impact factor: 17.440

4.  Covariation between plasma phosphate and daytime cortisol in early Parkinson's disease.

Authors:  Lena Håglin; Lennart Bäckman
Journal:  Brain Behav       Date:  2016-10-03       Impact factor: 2.708

5.  Hypophosphatemia is an independent risk factor for AKI among hospitalized patients with COVID-19 infection.

Authors:  Zijin Chen; Chenni Gao; Haijin Yu; Lin Lu; Jialin Liu; Wei Chen; Xiaogang Xiang; Hafiz Muhammad Jafar Hussain; Benjamin J Lee; Chuanlei Li; Wenjie Wei; Yuhan Huang; Xiang Li; Zhengying Fang; Shuwen Yu; Qinjie Weng; Yan Ouyang; Xiaofan Hu; Jun Tong; Jian Liu; Li Lin; Mingyu Liu; Xiaoman Xu; Dan Liu; Yuan Song; Xifeng Lv; Yixin Zha; Zhiyin Ye; Tingting Jiang; Jieshuang Jia; Xiaonong Chen; Yufang Bi; Jun Xue; Nan Chen; Weiguo Hu; Cijiang John He; Huiming Wang; Jun Liu; Jingyuan Xie
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.